We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Merck’s has reported a 42% decline in net income to 247 million euros ($283 million) for Q2, but new drugs Bavencio and Mavenclad helped the company maintain organic sales growth.